Response and effectiveness

Dupixent relieves the irritation associated with eczema in adults and adolescents within 2 to 4 weeks, and within 16 weeks, the state of the skin has significantly improved.

Dupixent reduced itching in studies on children with severe eczema aged 6 to 11 years old 4.5 times more frequently than a placebo (an inactive medicine). Additionally, twice as many kids on Dupixent experienced skin improvement with clear or almost clear skin.

For people with asthma, there was some improvement in lung function after two weeks, which became noticeable after 12 weeks and persisted for 52 weeks. Up to 81% less severe respiratory exacerbations occurred. About 86% of individuals cut back on or completely stop using oral steroids.

Adults with uncontrolled chronic rhinosinusitis and nasal polyps improved their sense of smell in as little as two weeks. Furthermore, in 24-week and 52-week clinical trials, over 80% fewer patients required nasal polyp surgery.

According to the manufacturer, it takes 16 weeks of Dupixent treatment to achieve steady-state levels.